The goal of longevity research is not only to extend lifespan but also to expand and optimize “Healthspan”.
Healthspan refers to the number of years a person lives in good health, free from chronic diseases and disabilities.
Zephyr Group, Inc (Zephyr)
Our mission is simple:
Optimize the healthy human healthspan through innovative biotechnology solutions.
The combination of advanced biotechnology innovations aligned with traditional remedies, adaptogenic herbs, essential bioactive compounds, and phytoceuticals, delivered via therapeutic wellness and lifestyle products, presents a myriad of greenfield investment and commercial opportunities.
FOCUS
Zephyr Well Positioned to Capitalize
- Patents for various product categories.
- Existing proprietary product compounds/formulations.
- Lead clinical asset for Type II Diabetes, Pain Management, Obesity, Skincare, and Mental health.
- Focus on “Precision Medicine”.
- Established cGMP Manufacturing.
- Domestic and International Joint Venture/Distribution Partners.
- University and Pharmaceutical Affiliations.
A convergence of PEPTIDES and PHYTOCEUTICALS combined with a focus on ANTI-Aging SCIENCE and PRECISION MEDICINE provides untapped opportunities to develop and introduce highly differentiated healthcare products.
Global Market
The biotech and nutraceutical industries are targeting some of the same lifestyle disease growth markets.
The Outlook – Market Size – Advancing Personalized Medicine
With the goal to optimize healthspan. We are developing innovative biotechnology solutions to tackle the challenges of Aging and improve the quality of life for individuals worldwide.
The Synergistic Power of Bioactive Compounds – A modern “plant-based” industrial revolution is emerging, the convergence of peptides and phytoceuticals represents a transformative shift in healthcare, wellness and sustainability.
INNOVATION
Utilizing emerging technologies ~ Advancing healthcare, Empowering lives.
BioTechnology
Biotechnology holds immense potential in extending healthspan and improving quality of life as we age.
- Research andBiomarkers
- Epigenetic Testing
- AI and New Drug Targets
- Pharmacological Interventions
- Nutrition and Supplements
Obesity and Diabetes
Diabetes is the leading cause of death in Mexico, killing nearly 80,000 people each year. In the US, diabetes is the sixth leading cause of death.
- Obesity is a worldwide epidemic caused by an increase in the consumption of foods with poor nutritional value
- The United States and Mexico have high rates of obesity and diabetes
- Our the diabetes product line could enhance Zephyr Group's market position and valuation.
FOCUS
At the forefront of our portfolio is a lead candidate addressing Type 2 diabetes that is demonstrating early clinical evidence of significant improvements in key health markers including blood glucose, hemoglobin A1c, cholesterol and triglycerides.
- Multinational (US and Mexico) protocol for clinical study submission of our patented natural type II diabetes compound
- Development of a new, effective, natural diabetes medication could have a profound impact on patients worldwide
- Significant improvements in key health markers, including blood glucose, hemoglobin A1c, cholesterol and triglycerides
- New molecular entities as well as novel drug delivery technologies, creating truly transformative treatments
- Development of the diabetes product line to enhance Zephyr Group's market position and valuation.
Trial Results: Graph shows average improvement in blood sugar and lipid values after 3 months of treatment
Whether it’s slowing the effects of aging, improving skin elasticity, reduce inflammation, or treating debilitating illness, Zephyr Group is at the forefront of medical innovation.
OPPORTUNITIES
We believe that our unique approach to drug development, which incorporates the development of new molecular entities as well as novel drug delivery technologies, will allow us to create truly transformative treatments with the potential to improve the lives of millions of people.
Capitalizing on the GLP-1 Receptor Agonist Trend
The surge in popularity of GLP-1 receptor agonists (GLP-1 RAs) presents a significant opportunity for various sectors.
New glucagon-like peptide 1 products
- GLP-1 has long been a pharmaceutical target as to obesity and diabetes. Most modern obesity drugs are based on the manipulation of GLP-1 and GIP. There is strong evidence that GLP-1 and the endocannabinoid CB1 receptor have strong interactions
- Zephyr is utilizing advanced technologies like AI and machine learning to identify new drug targets and develop innovative GLP-1 RA therapies.
The Opportunity of a Natural, Side-Effect-Free Alternative to GLP-1 Drugs
By addressing these challenges and capitalizing on the opportunities, a natural product line that effectively addresses the needs of consumers seeking safe and effective weight management solutions can carve a significant niche in the market.
The increasing public awareness of side effects associated with GLP-1 drugs like Ozempic and Semaglutide presents a significant opportunity for natural products that offer similar benefits without the drawbacks.
Fueled by the surge in demand for Novo Nordisk’s GLP-1 medication semaglutide and Eli Lilly’s GLP-1 and GIP drug tirzepatide, investors are increasingly eager to bet big money on the next generation of weight loss drugs.
Compounded Semaglutide associated with at least 10 deaths, Novo Nordisk CEO warns1
Ozempic Could Be Blinding People Trying to Lose Weight2
Peptides and Phytoceuticals
The Synergistic Power of Bioactive Compounds – A modern “plant-based” industrial revolution is emerging, the convergence of peptides and phytoceuticals represents a transformative shift in healthcare, wellness and sustainability.
Peptides and Phytoceuticals are two promising areas in the healthcare industry with significant potential for the development of innovative healthcare products.
Global peptide therapeutics market is expected to reach
USD 106.0 Billion by 2033.
Global phytoceuticals market is forecasted to reach
$1 trillion by 2030.
The Endocannabinoid System (ECS)
The relationship between diabetes and the ECS is a complex and fascinating area of research with significant implications for potential therapeutic interventions.
Research suggests that modulating the ECS could potentially slow down the aging process and improve healthspan
Zephyr researchers believe that by understanding the role of the ECS in aging and disease, that we can develop innovative strategies to improve human healthspan and longevity.
"What if there was a source of naturally-derived therapeutics to address the pressing health challenges we face today?"
– D. Roy Serventi, Zephyr Group Founder & CEO
STRATEGIC ACQUISITIONS
UNLEASHING OUR GROWTH POTENTIAL
In line with Zephyr's vision for growth, our management team recognizes the importance of a strong IP portfolio in solidifying our strategic position and enhancing our value proposition for present and future endeavors.
Through the utilization of proprietary, cost-effective formulations and innovative technologies, Zephyr is poised to pave the way for the development of a distinct and exceptional product brand pipeline.
STRATEGIC ACQUISITION A
Regain Your Natural Balance
Research lab with patents and focus on metabolic syndrome
GlycorX* – A Zephyr product
- Combination herbal mixture whose active ingredients have also been.
- Studied by research groups around the world.
- Ability to lower blood glucose levels.
- Study conducted in Israel by Dr. Dov Fogel and his team
- Human experimentation (Helsinki Commission, and trial registration ISRCTN 12562776).
- Patients average 37% drop on their blood glucose level.
- Effective in patients with high blood glucose levels.
* The product compound will be utilized in an upcoming bi-national clinical study in the US and Mexico.
STRATEGIC ACQUISITION B
Unique technology advances of research grade bio-identical ingredients positioned for patent applications and medical trials.
Zephyr has entered into a Letter of Intent (LOI) to acquire all assets and IP
Zephyr has entered into a Letter of Intent (LOI) to acquire all assets and IP
Bio Actives Cosmeceutical and Brand Development Platform
Bio Actives Cosmeceutical and Brand Development Platform
- Exceptional scientific and R&D advances
- World leader in synergistic combinations of bioactive ingredients for topical care products.
- Company has over 20 years of product ingredient development.
- Experts in advanced bio-identical peptide ingredients.
- Founded by renowned skin care scientist Dr. Hannah Sivak, PhD,.
Addressing Skin Concerns Related to Weight Loss
- Skin issues due to Rapid weight loss.
- Develop topical products associated with GLP-1 medications.
- Address skin issues like sagging, wrinkles, and loss of facial volume.
- Opportunity to develop products specifically to address these concerns.
Targeted Skincare Products
- Products focused on skin tightening, hydration, and collagen related to weight loss.
- Licensing opportunities with large consumer and pharmaceutical companies.
- Relationships with Barentz USA and Presperse distributors.
STRATEGIC ALLIANCES
Precision Medicine Platform and Advanced Healthcare Technology
Functional Health – International cGMP
Utilizing exclusive IBD (Integrated Bioscience Design) methodology. Focusing on product development of supplements and beauty manufacturing, offering skincare and functional health food solutions. With patented technology and a consistent pursuit of anti-aging and healthy living products.
Research and Development – Peptide R&D
- Development of novel proteins with potent enzymatic activity and high binding affinity.
- Cutting-edge library generation and screening approaches.
- Identify optimized proteins that exceed your expectations.
Precision Wellness Testing – Epigenetics and DNA testing platform
- Personalize health and wellness solutions.
- Analyzing individual DNA profiles
- Crafting tailored recommendations
- Optimize personal health outcomes.
- Wellness strategies tailored specifically to genetics.
Compound Pharmacy – High Quality Medications
- A state-of-the-art facility from the ground up.
- Meet the demands of custom, high quality medications.
- Bridge the gap of drug and treatment shortages.
- Excellent customer service toachieve the lifestyle they deserve
- Our 503A designated pharmacy exceeds the standards set by USP.
Zephyr addresses the challenges and capitalizes on the opportunities, with natural product lines that effectively address the needs of consumers seeking safe and effective solutions as we carve a significant niche in the market.
MARKETING STRATEGY
Our Differentiation: Position Zephyr as an innovator with a focus on:
Unique Mechanisms of Action – Improved Patient Outcomes – Strong Intellectual Property
Target Audience with a Wellness "Healthspan" and Holistic Healthcare focus
- DTC - Digital Marketing
- B2B - Direct-to-Physician/Clinician/Aesthetic Spas
- Key Opinion Leader (KOL) Engagement
Marketing Objectives:
- Launch and successfully commercialize the lead clinical asset for Type II Diabetes.
- Expand market share in existing product categories through product differentiation and enhanced marketing efforts.
- Secure new partnerships with domestic and international companies to expand market reach and accelerate product development.
- Build brand recognition as an innovative and reliable player in the nutraceutical and pharmaceutical industry
SALES STRATEGY
Sales Channels
Utilize DTC/E-commerce – Highly Skilled Sales Force – Leverage Distributor Networks
Sales Process
Clear Sales Stages – Identify Key Decision-Makers – Effective Communication Protocols.
Sales Automation – CRM Software – Data Analytics – Sales Enablement Tools.
Customer Relationship Management (CRM)
Implement Robust CRM system – CRM data
Personalize Customer Interactions and satisfaction CAC and LTV – Improve CAC and LTV Metrics
CURRENT PRODUCT LINE
Offering a comprehensive suite of healthcare and skincare solutions utilizing our proprietary Peptide and Phytoceutical compounds, our innovative solutions are designed to improve patient outcomes and enhance quality of life.
Zephyr Group is uniquely positioned to establish itself as an innovative plant-based biotech Company with an actionable acquisition pipeline and well-defined go-to-market growth strategy.
Investor Rationale
Zephyr Group is uniquely positioned to establish itself as an innovative plant-based biotech Company with an actionable acquisition pipeline and well-defined go-to-market growth strategy.
Highly Experienced and Motivated Team Prepared to Execute Strategy
- Seasoned industry veterans and management team with relevant industry experience — medical, nutraceutical, pharmaceutical R&D, consumer product goods, and investment banking experience fueled by an innovative spirit.
- Intellectual property ("IP") portfolio includes multiple biotechnology innovations, drug delivery systems, and patents to strengthen financial position.
- Novel products, unique formulations, and product delivery pipelines will propel market growth.
Well-Developed Roll-Up Strategy with Strong A Pipeline
- M&A targets that have been "vetted" and are ready to join the Zephyr platform.
- Close relationships with several potential targets for future consideration.
Diversified Revenue Streams with Significant Synergy Potential
- Established DTC and B2B business with the ability to scale and significantly grow revenue streams across the value chain.
- It's strategically aligned position allows Zephyr to adapt to shifting market demand.
"Unique technology advances of research grade bio-identical ingredients positioned for patent applications and medical trials."
– D. Roy Serventi, Zephyr Group Founder & CEO
THE TEAM
The Zephyr Group has assembled an outstanding leadership and strategic advisory team to spearhead the development and acquisition of cutting-edge technologies.
Boasting decades of expertise and proven success in the nutraceutical, cosmeceutical, cannaceutical, and pharmaceutical manufacturing and business sectors, our team is well-equipped to launch and oversee Zephyr's ambitious initiatives.
D. Roy Serventi
Founder and CEO
Jerry Washburn
Vice President – CFO
Dr. David Lorrabaquio Sanchez
Interim Chief Medical Director, Sr Advisor
Dr. Jeanette Jacknin, MD
Sr. Medical Advisor
Kevin Stock
Director of Integration & Brand Development
Judith S. Reyes
V.P. of Business Development and Operations
Amanda Vega
Director of Communications and Public Relations
Sean Kelley
Vice President of Marketingand eCommerce
Max Serventi
Logistics & Digital Marketing Manager
Sean Rosza
Chief Cultivator and Genetics Development
Hector Perez, MSOM
Senior Nutraceutical Formulator and Wellness Education Dir.
Enrique Rodriguez Macias
General Manager of Mexico Business Development
Nicholas Serventi
Financial Advisor
Dr. Luis David Suárez Rodríguez, MD
Sr. Medical Advisor
Pierre Sayad
Senior Advisor
Victoria Schwartz
Senior Advisor
Dr. Zoraida P. Aguilar, PhD, MS
Senior Advisor
Dr. Jaiprakash (Jai) Shewale, PhD
Senior Advisor
CONTACT US!
- 7135 East Camelback Rd. Suite 230 Scottsdale, AZ 85251